Cargando…

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

OBJECTIVE: To investigate the efficacy, safety, immunogenicity and pharmacokinetics of biosimilar adalimumab (ADL) PF-06410293 (ADL-PF; adalimumab-afzb) versus EU-sourced reference ADL (ADL-EU) in patients with active rheumatoid arthritis (RA) on longer-term treatment and after being switched from A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleischmann, Roy M, Alvarez, Daniel F, Bock, Amy E, Cronenberger, Carol, Vranic, Ivana, Zhang, Wuyan, Alten, Rieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061859/ https://www.ncbi.nlm.nih.gov/pubmed/33883254 http://dx.doi.org/10.1136/rmdopen-2021-001578

Ejemplares similares

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2022)

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
por: Alten, Rieke, et al.
Publicado: (2019)

Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects
por: Cox, Donna S., et al.
Publicado: (2021)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Recent advances in ADL, CutLang and adl2tnm
por: Unel, Gokhan
Publicado: (2021)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
por: Genovese, Mark C, et al.
Publicado: (2020)

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis
por: Kay, Jonathan, et al.
Publicado: (2022)

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study
por: Buttgereit, Frank, et al.
Publicado: (2019)

Prediction for doubly charged Higgs using ADL
por: Ohrnberg, Ronja
Publicado: (2022)

FuncADL: Functional Analysis Description Language
por: Proffitt, Mason
Publicado: (2021)

EDUCATION AND PERCEIVED FUTURE NEED FOR ADL HELP
por: Finan, Julia
Publicado: (2022)

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Robinson, Michael F., et al.
Publicado: (2020)

Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment
por: Alten, Rieke, et al.
Publicado: (2014)

The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial
por: Winkler, Aaron, et al.
Publicado: (2021)

Predictors of ADL Disability in Culturally Diverse Older Adults
por: WINCHESTER, FERNANDA, et al.
Publicado: (2009)

Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis
por: de Meel, R. H. P., et al.
Publicado: (2018)

Development and content validation of an ADL questionnaire for hemiplegic shoulder
por: Chatterjee, Subhasish, et al.
Publicado: (2023)

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
por: Burmester, Gerd R, et al.
Publicado: (2017)

Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2015)

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
por: Matucci-Cerinic, Marco, et al.
Publicado: (2018)

Brief Report: Estimating Disease Activity Using Multi‐Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
por: Fleischmann, Roy, et al.
Publicado: (2016)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment
por: Taylor, Peter C, et al.
Publicado: (2018)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Validity and reliability of the Arabic version of Activities of Daily Living (ADL)
por: Nasser, Ramzi, et al.
Publicado: (2009)

The Onset of ADL Difficulties and Changes in Health-Related Quality of Life
por: Lyu, Wei, et al.
Publicado: (2017)

Depressive symptoms in individuals with family members requiring ADL assistance
por: Kwon, Junhyun, et al.
Publicado: (2019)

An Evaluation of Graphical Formats for the Summary of Activities of Daily Living (ADLs)
por: Byrne, Caroline A., et al.
Publicado: (2020)

Rank Pooling Approach for Wearable Sensor-Based ADLs Recognition
por: Nisar, Muhammad Adeel, et al.
Publicado: (2020)

Determinants of ADL and IADL disability in older adults in southeastern Poland
por: Ćwirlej-Sozańska, Agnieszka, et al.
Publicado: (2019)

Inertial Data-Based AI Approaches for ADL and Fall Recognition
por: Martins, Luís M., et al.
Publicado: (2022)

Biosimilars in rheumatology: what the clinician should know
por: Castañeda-Hernández, Gilberto, et al.
Publicado: (2015)

Era of biosimilars in rheumatology: reshaping the healthcare environment
por: Smolen, Josef S, et al.
Publicado: (2019)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e5qpafrrd4822oevfni978adm9